Medical Xpress March 23, 2025
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss. Unfortunately, shortages and high costs have made it difficult for people to start and maintain treatment.
Now, researchers report a drug delivery system that “paints” these peptides directly on the antibodies they target. In studies with mice, the system led to sustained weight loss and prolonged blood sugar management with a GLP-1 injection one fourth that of the standard dose.
Bradley Pentelute, professor of chemistry at the Massachusetts Institute of Technology (MIT), presents his team’s results at the spring meeting of the American Chemical Society (ACS 2025) held March 23–27 in San Diego.
Peptide-based therapies are highly effective. However, they are easily degraded by enzymes...
Today's Sponsors
Today's Sponsor